What a fantastic story! That's how science should be done.

An inhibitory ligand acts directly on CD3e to regulate T cell activation, and disruption of the interaction boosts tumor-specific T cell cytotoxicity to limit tumor growth Cell cell.com/cell/fulltext/…

Can precision medicine based ex vivo drug screens using patient samples work for children? This study demonstrates that the answer may be yes. nature.com/articles/s4159…

ACGT Research Fellows, and members of the ACGT Scientific Advisory Council, Carl June, MD (Penn), and Michel Sadelain, MD, PhD (Memorial Sloan Kettering Cancer Center), received the Breakthrough Prize for Life Sciences on Saturday! (1/3)

🚨We are hiring a Research Assistant to help us supercharge CAR T cells! Candidates of all experience levels are encouraged to apply. Some lab experience is required, mouse experience is preferred. 2-year minimum commitment. Please retweet! Apply here: chop.wd5.myworkdayjobs.com/CHOPExternalCa…

💉 Overcoming T-cell inhibition via the PD-1/PD-L1 axis is a critical challenge in CAR-T cell therapy 📝 Our latest publication in Nature Communications unveils how CAR-antigen affinity could pivotally influence T-cell susceptibility to this axis ⬇️

Safety and anti-tumor activity of autologous Her2 CART in sarcoma. Congratulations Nabil, Meena and the extended team Center for Cell and Gene Therapy and beyond nature.com/articles/s4301…

Excited to share our collaborative work on identifying CART targets for pediatric cancer by exon level expression nature.com/articles/s4146… St. Jude St. Jude Research Nature Portfolio

🚀 Join Our Team at Baylor College of Medicine! 🧬 We’re looking for passionate technician to join our lab at Center for Cell and Gene Therapy. Help us develop innovative and accessible cell therapies for cancer and autoimmunity using genome editing. Pls RT 🙏 jobs.bcm.edu/job/Research-T…

Like many disruptive technologies, engineered T-cell therapies follow the Gartner hype cycle. We are approaching the second upward slope.

Matt Rea was treated with CD19 CART cells back in 2010 at Baylor Center for Cell and Gene Therapy and has been cancer-free since then, for 14 years. The CAR-T were made from his twin brother. Is he the longest surviving CAR-T patient? blogs.bcm.edu/2024/06/04/fol…

The answer is NO. Here's a patient with neuroblastoma who was treated 18 years ago with GD2.CAR T cells at Baylor Center for Cell and Gene Therapy and still remains in remission. We need more of these stories. researchsquare.com/article/rs-423…

Limiting institutional overhead on NIH grants?

Comprehensive thread highlighting our most recent work now out in Cell Stem Cell describing a novel approach to increase persistence of allogeneic cell therapy products. Work led by amazing Quirin Hammer and Karlo Perica. Precision Immunotherapy Alliance, Oslounivsykehus UiO - Det medisinske fakultet Karolinska Institutet

Are all hybrid antigen receptors as easy to design as CARs? Definitely not! doi.org/10.1158/2159-8… (1/4)

Congrats to the now Dr. Ruchi Patel for the publication of her PhD thesis in Science Immunology. We show here that CD5 deletion enhances CART immunotherapy in multiple solid and liquid cancer models. Penn Medicine Ruella Lab science.org/doi/10.1126/sc…

T cells express a ton of CD5, so why CD5 CAR T cells don't kill each other? Turns out, they completely degrade CD5 protein and thus evade fratricide. Unique mechanism unveiled in a mechanistic study - and PhD thesis work - by Royce Ma: cell.com/cell-reports-m…

The genomic basis of childhood T-lineage acute lymphoblastic leukaemia | Nature nature.com/articles/s4158…

Excellent results with autologous CD7-PEBL CART in T-ALL from Singapore and Rome nature.com/articles/s4159…

An interesting POC of T cell therapy in CNS injury models: autoreactive MOG-specific T cells infiltrate the lesion and suppress tissue damage, counter-intuitively in part via IFNg secretion. But you have to act fast. nature.com/articles/s4158…